Sofie D.
- Country
- Belgium
- Department
- Oncology
Research Overview
- A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study of JNJ-78278343, a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer
- A Phase 3 Study of Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy
Data & Insights
Has run more than one trial at 50 of 133 partner sites.
Specializations
Urologic Oncology
The investigator specializes in the treatment of muscle-invasive urothelial carcinoma, focusing on advanced therapeutic approaches for bladder and urinary tract cancers.
- Bladder Cancer Management
- Urothelial Carcinoma Treatment
- Muscle-Invasive Disease
Expertise extends to high-risk urological malignancies and their therapeutic management.
Immunotherapy Research
Primary focus includes the application of immunotherapeutic approaches in urological cancers, particularly investigating combination treatment strategies.
- Novel Immunotherapy Combinations
- Targeted Cancer Treatments
- Adjuvant Therapy Development
Specializes in evaluating innovative immunological interventions for cancer treatment.
Disease Surveillance
Expertise in monitoring disease-free survival and treatment outcomes in urologic cancer patients, with emphasis on long-term patient follow-up.
- Treatment Response Assessment
- Clinical Outcomes Evaluation
- Risk Assessment Strategies
Focuses on investigating therapeutic effectiveness through clinical assessment methodologies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.